Remarkably, we measured significantly higher anti-IFI16 titers in SLE patients compared with both disease and control groups, and, according to cutoff levels, we were able to estimate that more than 60% of the SLE patients tested positive for anti-IFI16 autoantibodies compared with just 24% of patients with primary non-SLE GN and 5% of healthy individuals. This evidence concerns the gene IFI16 and systemic lupus erythematosus.